Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Obexelimab (CD19xFcyRIIb) in Systemic lupus erythematosus. The expected timing is based on the latest available company guidance and may change.
SunStone trial. 11/12/24- Trial initiated. 5/15/25- Enrollment completion by YE 2025. 8/12/25- Topline data in mid-2026. 11/12/25:- SunStone Ph2 enrollment completion YE 2025; topline data expected Mid-2026. 01/05/26:- SunStone Ph2 SLE topline and biomarker data now expected in Q4 2026. 03/16/26:- Reiterated SunStone Ph2 SLE topline and biomarker data expected in Q4 2026. 05/13/26:- SunStone Ph2 SLE enrollment complete; topline and biomarker results expected in Q4 2026. 08/13/26:- SunStone Ph2 SLE topline and biomarker results are expected in Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.